# Biosion

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biosion

- Industry: Biotechnology
- Headquarters: Nanjing, China
- Website: www.biosion.com
- Total disclosed funding: $19M
- Latest round: Series B (Apr 23, 2023)
- Investors on record: 7

## About

Established in 2017 and based in Nanjing, China, Biosion, Inc. is a biotechnology company that engages in the research and development and production of antibody drugs for tumors and immune diseases. Dr. Mingjiu Chen, the company's founder, used to work as a senior scientist at AbbVie. It has oversea offices in the US and Australia. In April 2023, it raised series B+ funding from new investors Ruiying Holdings, Harmony Venture, and an individual investor. The company engages in the research and development and production of antibody drugs for immune and oncologic diseases. It self-developed the H3 antibody discovery platform, SynAb collaborative antibody discovery platform, and SynTracer antibody endocytosis screening platform. The H3 antibody discovery platform provides high-throughput, high-capacity screening services for drug molecules. It developed mono and bi-specific protein therapeutics, antibody-drug conjugates, and macrophage reprogramming agents for oncology and immunology. Its main product, BSI-045B (anti-TSLP mAb), is in phase II for severe asthma and phase-I for atopic dermatitis. n August 2025, Biosion, Inc. closed a venture funding from new investor Huangpu Biomedical Investment, Guangzhou Xinxing Fund, and Shenzhen Oriental Huisheng Capital Management.

## Funding rounds

- Series B, Apr 23, 2023 — Harmony Venture, Ruiying Capital
- Series B, Dec 28, 2022, $14M — Fang Fund Partners, GF Xinde Investment, Addor Capital, Suzhou Trust
- Series A, Oct 29, 2017, $4.5M — Renhe Capital

## Investors

- Renhe Capital (https://capitalatlas.ai/funds/renhe-capital) — Series A
- Fang Fund Partners (https://capitalatlas.ai/funds/fang-fund-partners) — Series B
- GF Xinde Investment (https://capitalatlas.ai/funds/gf-xinde-investment) — Series B
- Addor Capital (https://capitalatlas.ai/funds/addor-capital) — Series B
- Suzhou Trust — Series B
- Harmony Venture (https://capitalatlas.ai/funds/harmony-venture) — Series B
- Ruiying Capital (https://capitalatlas.ai/funds/ruiying-capital) — Series B